Pseudomonas

Pseudomonas is one of the few organisms on a gut panel that almost nobody carries in meaningful amounts when things are going well. It's an environmental bacterium, common in soil and water, and it isn't a core member of the human gut community. So when it shows up, the question worth asking is why there was an opening for it.

That framing matters because this organism is deliberately left off every standard clinical stool panel. The BioFire FilmArray, the QIAstat-Dx, and similar assays target the classic diarrhea-causing pathogens and skip Pseudomonas entirely, because it doesn't cause ordinary community-acquired gastroenteritis. A clean result on one of those panels says nothing about this organism either way.

What This Test Actually Detects

The assay amplifies Pseudomonas DNA from your stool. It counts genetic material from bacteria sitting in your intestine or passing through it. The technique is PCR, which copies a target stretch of DNA over and over until there's enough of it to detect.

PCR is extremely sensitive, and that cuts both ways. It picks up DNA from dead bacteria, from organisms that arrived on a salad three hours ago, and from genuine residents. The test can't tell you which. That limitation runs through all molecular stool testing: amplifying DNA cannot separate an active infection from harmless carriage, or from the shed remains of bacteria that are no longer alive.

Detection isn't the same as disease, either. Pseudomonas causing actual gastrointestinal illness is rare, and largely confined to people who are profoundly immunosuppressed, who have very low white blood cell counts, or who are recovering from severe antibiotic-driven disruption of their normal gut bacteria. In otherwise healthy adults it has turned up as a cause of antibiotic-associated diarrhea only in isolated case reports.

Inflammatory Bowel Disease

The strongest human signal linking this organism to gut disease comes from inflammatory bowel disease, and it comes with a catch about where the bacteria actually live.

A case-control study comparing several sampling sites in people with inflammatory bowel disease found Pseudomonas species clearly enriched in the gut mucosa. That's the tissue lining the intestinal wall. In matched stool samples from the same people, the signal was absent. The bacteria were sticking to inflamed tissue rather than washing out into the stool.

An earlier study of ileal biopsies in children found Pseudomonas DNA in 58% of those with Crohn's disease compared with 33% of non-IBD controls. Pseudomonas aeruginosa specifically, the species behind most human infections, turned up only in the non-IBD tissue.

So a negative stool result doesn't rule out colonization of the mucosa, and a positive one isn't proof of inflammatory bowel disease. If you have gut symptoms and a positive result, the informative next step is measuring inflammation directly rather than chasing the organism.

Antibiotic Exposure and Resistance

Broad-spectrum antibiotics clear out the resident bacteria that normally crowd Pseudomonas out, and the organism expands into the space. This is the most common reason a healthy-looking adult picks up a positive result.

The bigger concern is what those strains carry. A surveillance study of 458 patients, built around people with chronic kidney disease, found fecal carriage of Pseudomonas aeruginosa in roughly 9% overall, concentrated in the kidney disease group. Most of the isolates carried extended-spectrum beta-lactamase genes. Those genes let bacteria destroy many common antibiotics before the drugs can work. About three quarters of the isolates resisted multiple drug classes.

A resistant strain in your gut is a reservoir, not an infection. It matters most if you later need surgery, chemotherapy, or a hospital stay, because gut colonization is a documented predictor of later clinical infection in intensive care populations.

Immunosuppression and Critical Illness

The clearest evidence that carriage predicts something bad comes from hospital settings, not from healthy outpatients. In intensive care cohorts, prior rectal colonization predicted later Pseudomonas clinical infection, and colonization itself is common in that setting.

But colonization isn't a required step. Surveillance in people with acute myeloid leukemia found bloodstream infections developing without the organism ever dominating the gut community first. A low stool number is not reassurance.

If you take immunosuppressive drugs, are on biologic therapy for an autoimmune condition, or have chronic kidney disease, a positive result is worth raising with your clinician. Not to treat it, but to have it in the chart before any procedure that breaks a barrier.

What Can Throw the Result Off

Interpretation here is exploratory. No validated clinical reference range exists for stool Pseudomonas, and baseline levels in healthy people sit so low that they often fall below the cutoffs sequencing-based tests use. Nobody has established what number should worry you.

• Recent antibiotics: a course finished in the past few weeks can push this organism up temporarily while your normal bacteria are recovering. The reading reflects the disruption, not a stable state.
• Transient passage: Pseudomonas is common in water and on produce. DNA from organisms that simply passed through your gut over a day or two looks identical to DNA from residents.
• Non-viable DNA: PCR detects dead bacteria. Stool pathogen DNA has been shown to stay detectable three weeks after successful antibiotic treatment.
• Stool consistency and transit: how fast material moves through you, and how much water is in the sample, shift measured abundance for reasons that have nothing to do with disease.

Why One Reading Is Not Enough

Serial testing is the practical way to separate a pass-through from a resident. A single positive tells you the organism's DNA was in that sample on that day. Two positives months apart, with no antibiotic course in between, make persistent colonization far more likely, though DNA alone still can't confirm the bacteria are alive.

Your gut community is among the more stable microbiomes you have. In healthy people followed for up to six years, stool and oral communities changed much more slowly than skin or nasal ones. That stability is what makes trending useful: a real shift away from your own baseline means something in a way a single snapshot never does. Stability is lower in some groups, though. People with insulin resistance had measurably less stable stool microbiomes than insulin-sensitive people, with wider swings after a disturbance.

What To Do With an Unexpected Result

Detection alone isn't a reason to take an antibiotic. Treating asymptomatic colonization has no demonstrated benefit, and Pseudomonas is among the harder organisms to eradicate, with resistance mechanisms that often make the attempt counterproductive.

The productive move is to ask whether anything is inflamed. Fecal calprotectin measures immune cells migrating into the gut lining, which separates genuine inflammation there from a functional problem. If calprotectin is normal and you feel fine, a positive Pseudomonas result is most likely carriage. If calprotectin is up, the organism is probably a passenger riding a barrier problem, and the barrier is what needs attention.

A few patterns change the calculus. Detection alongside fever, bloody stool, or rapid weight loss warrants same-week evaluation, not watchful waiting. Detection in someone on immunosuppressive therapy, in dialysis, or heading into surgery is worth flagging to the treating clinician so it sits in the chart. And detection with a normal inflammatory workup but persistent symptoms points toward a gastroenterology evaluation that looks at the mucosa directly, since that's where this organism lives when it matters.

Culture still does something PCR can't. If a clinician decides the organism is causing disease, only a culture will tell you which antibiotics work, because PCR reads DNA and can't test whether a live organism survives a drug.